Results 11 to 20 of about 99,431 (234)

Predictors for low coverage of uptake of second dose of measles vaccine among children in sub-Saharan Africa, 2023: a systematic review and meta-analysis [PDF]

Journal of Pharmaceutical Policy and Practice
Background Measles became a public health important disease in sub-Saharan Africa. World Health Organization recommended measles-containing vaccine dose 2 (MCV2) through routine service delivery.
Tamirat Melis, Ayenew Mose, Yohannes Fikadu, Kassahun Haile, Aklilu Habte, Gemechu Jofiro   +5 more
doaj   +2 more sources

Cross-sectional Survey on Parental Perception and Attitude on Measles Vaccine: Low Hospital Measles Case Presentation in Rural Area in Enugu, Nigeria [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: The incidence of measles has spiked in recent times despite the efforts to its eradication using a highly effective measles vaccine. Vaccine coverage and underreporting of cases are the major challenges to this effort.
Chukwuemeka Chijoke Nwangwu, Amadi Emmanuel Chike, Imanyikwa Olaedo Eucharia Ijeoma   +2 more
doaj   +1 more source

Geographical and time trends of measles incidence and measles vaccination coverage and their correlation in Nigeria

Human Vaccines & Immunotherapeutics, 2022
Nigeria has one of the highest measles burdens in the world. While measles-containing vaccine is proven to be effective in reducing measles cases, empirical studies on the correlation between measles incidence and measles vaccine coverage in Nigeria has ...
Ryoko Sato, Olusesan Ayodeji Makinde, Koeloengan Clement Daam, Bola Lawal   +3 more
doaj   +1 more source

Two cases of measles after vaccination with measles mumps and rubella combined live attenuated vaccine

Shanghai yufang yixue, 2022
Measles is an acute respiratory infectious disease caused by the measles virus. It is highly infectious and easy to occur in children. It causes many serious complications such as tracheitis， otitis media and pneumonia. Since the promotion of the measles
SHEN Jinhua, HU Tajing, CHEN Wenhua, QIAN Jingxian, LU Hongmei   +4 more
doaj   +1 more source

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors

Molecular Therapy: Oncolytics, 2016
To target oncolytic measles viruses (MV) to tumors, we exploit the binding specificity of designed ankyrin repeat proteins (DARPins). These DARPin-MVs have high tumor selectivity while maintaining excellent oncolytic potency.
Jan RH Hanauer, Lisa Gottschlich, Dennis Riehl, Tillmann Rusch, Vivian Koch, Katrin Friedrich, Stefan Hutzler, Steffen Prüfer, Thorsten Friedel, Kay-Martin Hanschmann, Robert C Münch, Christian Jost, Andreas Plückthun, Klaus Cichutek, Christian J Buchholz, Michael D Mühlebach   +15 more
doaj   +1 more source

Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China. [PDF]

PLoS ONE, 2017
The safety of measles vaccination is of great interest and importance to public health practice and the general society. We have analyzed the adverse events following immunization (AEFIs) of currently used measles-containing vaccines (including live ...
Fan-Ya Meng, Yong Sun, Yong-Gang Shen, Hai-Feng Pan, Ji-Hai Tang, Bin-Bing Wang, Chang-Hao Wu, Dong-Qing Ye   +7 more
doaj   +1 more source

Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models [PDF]

, 2009
We evaluated the effectiveness of a measles vaccine campaign in rural Kenya, based on oral-fluid surveys and mixture-modelling analysis. Specimens were collected from 886 children aged 9 months to 14 years pre-campaign and from a comparison sample of 598
E. O. OHUMA, E. A. OKIRO, A. BETT, J. ABWAO, S. WERE, D. SAMUEL, A. VYSE, N. GAY, D. W. G. BROWN, D. J. NOKES, Nokes, Vyse, Kremer, Enquselassie   +13 more
core   +1 more source

High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency

Molecular Therapy: Oncolytics, 2019
Measles virus (MeV) is naturally cytolytic by extensive cell-to-cell fusion. Vaccine-derived MeV is toxic for cancer cells and is clinically tested as oncolytic virus.
Jan R.H. Hanauer, Vivian Koch, Ulrich M. Lauer, Michael D. Mühlebach   +3 more
doaj   +1 more source

A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. [PDF]

, 2014
Observational studies and trials from low-income countries indicate that measles vaccine has beneficial nonspecific effects, protecting against non-measles-related mortality.
Aaby, Aaby, Aaby, Aaby, Aaby, Aaby, Aaby, Aaby, Aaby, Aaby, Aaby, Aaby, Amabelia Rodrigues, Andreas Andersen, Barnard, Benn, Benn, Benn, Benn, Carlito Balé, Cesario L. Martins, Christine S. Benn, Clemens, de Quadros, Desgrées du Loû, Fischer, Fisker, Frederik Schaltz-Buchholzer, Garly, Graham, Greenwood, Henrik Ravn, Hilton Whittle, Holt, Kleinnijenhuis, Koenig, Lindblad, Lisse, Martins, Martins, May-Lill Garly, Moran, O'Dempsey, Peter Aaby, Rodrigues, Shaheen, Shann, Sørup, Sørup, The Kasongo project team, Ursing, Veirum, Vu An Do, Welsh, World Health Organization   +54 more
core   +2 more sources

Measles Vaccine [PDF]

Viral Immunology, 2018
Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vaccine. The current measles virus (MeV) vaccine was developed empirically by attenuation of wild-type (WT) MeV by in vitro passage in human and chicken cells and licensed in 1963.
openaire   +2 more sources